Ionis Chief Scientific Officer C. Frank Bennett, Ph.D. to receive Rainwater Prize for Outstanding Innovation in Neurodegenerative Disease Research

About this update from Ionis Pharmaceuticals, Inc.

[{"type":"text","content":"CARLSBAD, Calif., Jan. 26, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Chief Scientific Officer C. Frank Bennett, Ph.D., has been named a co-recipient of the Rainwater Prize for Outstanding Innovation in Neurodegenerative Disease Research. Dr. Bennett shares this year's prize with Don W. Cleveland, Ph.D., chair and distinguished professor of cellular and molecular medicine at University of California, San Diego and Timothy M. Miller, M.D., Ph.D., vice chair of research and David Clayson professor of neurology at Washington University School of Medicine. The prizes will be presented during the Eurotau 2023 conference on April 27, 2023, in Lille, France.\n\n \n \n \n \n \n \n\n \nDrs. Bennett, Cleveland and Miller are being recognized for their work advancing antisense technology for the treatment of neurodegenerative diseases including amyotrophic lateral sclerosis (ALS), Huntington's disease, Alzheimer's disease and tauopathies. Their long-term collaboration has resulted in four investigational medicines entering clinical studies, including tofersen, currently under regulatory review for market authorization for the treatment of SOD1-ALS, with a Prescription Drug User Fee Act (PDUFA) action date of April 25, 2023; tominersen, currently in a Phase 2 clinical study for the treatment of Huntington's Disease; and IONIS-MAPTRx/BIIB080, for the treatment of Alzheimer's disease, frontotemporal degeneration and progressive supranuclear palsy. The foundational science the team established was pivotal to the advancement of SPINRAZA® (nusinersen), for the treatment of spinal muscular atrophy, into clinical studies and ultimately approval in 2016.\n\"I'm humbled to be recognized by the Rainwater Charitable Foundation with this prestigious award. It represents an affirmation for the work that everyone at Ionis is doing to deliver transformational genetic medicines to patients battling grave diseases,\" said Dr. Bennett. \"I am equally honored to share the prize with my esteemed colleagues, Drs. Cleveland and Miller, whose expertise, dedication and tireless efforts have contributed significantly to bringing hope to patients and their families.\"\nA founding member of Ionis, Dr. Bennett is responsible for continuing to advance Ionis' technology and expand its discovery platform. He is also the franchise...

More updates from Ionis Pharmaceuticals, Inc.